1. |
World Health Organization. The top 10 causes of death. (2020-12-09)[2021-07-23]. https://www.who.int/en/news-room/fact-sheets/detail/the-top-10-causes-of-death.
|
2. |
World Health Organization. Chronic obstructive pulmonary disease (COPD). (2021-06-21)[2021-07-23]. https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd).
|
3. |
Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet, 2018, 391(10131): 1706-1717.
|
4. |
赵佳, 赵雅静, 安艳春, 等. 慢性阻塞性肺疾病急性加重患者 30 d 内不同预后的临床数据分析. 临床急诊杂志, 2020, 21(1): 65-69.
|
5. |
Adeloye D, Chua S, Lee C, et al. Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J Glob Health, 2015, 5(2): 20415.
|
6. |
Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med, 2013, 187(4): 347-365.
|
7. |
贾盼红, 李琪, 熊晓嫚, 等. 基于中性粒细胞弹力蛋白酶介导的通路研究地胆头干预慢性阻塞性肺疾病患者气道黏液高分泌及疗效观察. 海南医学院学报, 2021, 27(2): 101-104, 110.
|
8. |
Yang G, Wang Y, Zeng Y, et al. Rapid health transition in China, 1990-2010: findings from the global burden of disease study 2010. Lancet, 2013, 381(9882): 1987-2015.
|
9. |
世界中医药学会联合会. 国际中医临床实践指南 慢性阻塞性肺疾病. 世界中医药, 2020, 15(7): 1084-1092.
|
10. |
刘娅钦, 马丽, 刘琳. 慢性阻塞性肺疾病发病机制的研究进展. 临床肺科杂志, 2016, 21(6): 1113-1117.
|
11. |
李天浩, 韩晨旭, 王惠琴, 等. 基于 EGFR-MUC5AC 信号通路探讨参鱼化痰口服液干预慢性阻塞性肺疾病大鼠气道黏液高分泌的机制. 陕西中医, 2019, 40(8): 995-997, 1017.
|
12. |
赖异, 李雯. 黏蛋白 MUC5AC 在慢性阻塞性肺疾病患者气道中的表达及其临床意义. 华中科技大学学报(医学版), 2009, 38(3): 385-388.
|
13. |
王骏, 李春盈, 刘治坤, 等. 慢性阻塞性肺疾病气道黏液高分泌大鼠模型的建立. 心肺血管病杂志, 2014, 33(4): 592-595.
|
14. |
曾春芳. NE 在 COPD 患者肺组织中的表达及其与巨噬细胞凋亡的相关性研究. 西南医科大学学报, 2017, 40(4): 397-401.
|
15. |
田君才, 杜国亮, 张桂霞. 人工免疫组化判定结果与灰度值相关性. 临床与实验病理学杂志, 2010, 26(1): 112-113.
|
16. |
Negewo NA, Gibson PG, McDonald VM. COPD and its comorbidities: impact, measurement and mechanisms. Respirology, 2015, 20(8): 1160-1171.
|
17. |
Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2012, 186(2): 155-161.
|
18. |
Decramer M, Janssens W. Chronic obstructive pulmonary disease and comorbidities. Lancet Respir Med, 2013, 1(1): 73-83.
|
19. |
Faner R, Cruz T, López-Giraldo A, et al. Network medicine, multimorbidity and the lung in the elderly. Eur Respir J, 2014, 44(3): 775-788.
|
20. |
Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome?. Lancet, 2007, 370(9589): 797-799.
|
21. |
文富强, 申永春. 祛痰治疗在慢性阻塞性肺疾病中临床应用. 中华肺部疾病杂志(电子版), 2010, 3(4): 236-238.
|
22. |
柏正平, 刘雨, 谭小宁, 等. 金水六君煎对慢性阻塞性肺疾病气道黏液高分泌大鼠 肺组织黏蛋白 5AC 及水通道蛋白 5 表达的影响. 中国中医药信息杂志, 2019, 26(8): 54-59.
|
23. |
Gehrig S, Duerr J, Weitnauer M, et al. Lack of neutrophil elastase reduces inflammation, mucus hypersecretion, and emphysema, but not mucus obstruction, in mice with cystic fibrosis-like lung disease. Am J Respir Crit Care Med, 2014, 189(9): 1082-1092.
|
24. |
李西西, 梁余良, 张娟, 等. 中性粒细胞弹性蛋白酶及其在急性肺损伤中的应用. 预防医学论坛, 2017, 23(1): 74-76.
|
25. |
Hayakawa T, Naruse S, Kitagawa M, et al. Elastase. Nihon Rinsho, 1995, 53(5): 1192-1197.
|
26. |
Wang S, Guo H, Wang X, et al. Pretreatment with Danhong injection protects the brain against ischemia-reperfusion injury. Neural Regen Res, 2014, 9(15): 1453-1459.
|
27. |
Atanasova KR, Reznikov LR. Strategies for measuring airway mucus and mucins. Respir Res, 2019, 20(1): 261.
|
28. |
Lu W, Liu X, Wang T, et al. Elevated MUC1 and MUC5AC mucin protein levels in airway mucus of critical ill COVID-19 patients. J Med Virol, 2021, 93(2): 582-584.
|
29. |
Krishn SR, Ganguly K, Kaur S, et al. Ramifications of secreted mucin MUC5AC in malignant journey: a holistic view. Carcinogenesis, 2018, 39(5): 633-651.
|